Evidence map›Paper›PMID 37269389›Full record

ArticleAnnals of hematology2023

Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time.

Marko Lucijanic, Petra Veic, Ivona Aric, Katarina Marija Tupek, Ena Soric, Anica Sabljic, Josipa Vlasac Glasnovic, Tajana Stoos-Veic, Ivan Krecak, Rajko Kusec

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Marko LucijanicHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia. markolucijanic@yahoo.com.ORCID http://orcid.org/0000-0002-1372-2040
Petra VeicInternal Medicine Department, School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia.
Ivona AricClinical Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia.
Katarina Marija TupekClinical Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia.
Ena SoricHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Anica SabljicHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Josipa Vlasac GlasnovicHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
Tajana Stoos-VeicPathology and Cytology Department, University Hospital Dubrava, Zagreb, Croatia.
Ivan KrecakDepartment of Internal Medicine, General Hospital of Sibenik-Knin County, Sibenik, Croatia.
Rajko KusecHematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia.
University Hospital Dubrava · HRUniversity of Zagreb · HRUniversity of Rijeka · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myeloproliferative DisordersNeoplasmsRenal Insufficiency, ChronicAllelesHumansJanus Kinase 2KidneyMutationPrevalenceJAK2 protein, humanJanus Kinase 2

Identifiers

PMID37269389
OpenAlexW4379209760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.